Ubrogepant appears to prevent acute migraine
Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.
Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.
A new analysis of data from a large study of women’s health shows no link between a history of migraine and the risk of developing Parkinson’s disease (PD)…. read more.
A drug used to prevent migraine may also be effective in people with migraine who experience rebound headaches, according to a new study published in the June 26,… read more.
28th EAHP Congress Highlights No fewer than 11 posters from Spanish pharmacists dealt with the use of monoclonal antibodies in the management of migraine. Anti-CGRP (calcitonin gene-related peptide)… read more.
For middle-aged women plagued by migraines, or hot flashes and night sweats, another worry may linger in the backs of their minds: whether these experiences have set them… read more.
Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.
Migraine is more than just a headache. Often the pain is accompanied by nausea, vomiting, light sensitivity, and sound sensitivity. Chronic migraine can be disabling and may prevent… read more.
Research published in the European Journal of Neurology indicates that COVID-19 and COVID-19 vaccination have negligible effects on migraine severity. Among 550 adults who had received migraine-related care at a… read more.
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
When women suffer migraine attacks, it is often just before or during their monthly period. A team of researchers from Charité – Universitätsmedizin Berlin has now identified a… read more.
Migraine is a major cause of disability, affecting about 12% of people. A 2-part series published in CMAJ (Canadian Medical Association Journal) on diagnosing and managing the condition with both… read more.
Lidocaine infusions appear to offer significant relief to patients with refractory chronic migraine. Researchers reported this finding on May 23, 2022 in the journal Regional Anesthesia & Pain Medicine…. read more.